When it comes to one of its potential new drugs, Watson Pharmaceuticals
In case you were wondering exactly what onychomycosis is (and especially considering that's not exactly a word you'd want to say five times really fast), it's garden-variety nail fungus. Yucky, but common.
According to the National Society Onychomycosis Society website (which offers a section on "Fun Fungus Facts," bless their hearts), about 30 million people suffer from the ailment, with 11 million new cases diagnosed every year. Anyone, at any age, can get it and many of us will likely see it in our futures -- it tends to strike people between the ages of 40 and 65.
While this is a disorder that many may consider cosmetic and harmless, pictures on that website sure do make a case for getting treatment.
There are already several medications for nail fungus on the market. These include Novartis AG's
As it stands now, Watson said it will take the next six to eight weeks to weigh its options on the patch. The company had previously anticipated submitting it to the FDA in 2004, in the hopes of garnering approval in 2005.
While it's certainly a bummer, this piece of news doesn't seem like cause for too much alarm. While common, it's a disorder that many people ignore, and there's entrenched competition in Lamisil.
And as Jeff Hwang pointed out in November after robust earnings, Watson's stolen the show recently, with imminent launches of generic versions of Glucotrol, Percocet, and Serzone, among other compelling factors. So, like a stubbed toe, the pain related to this particular frustrated trial may be fleeting.
Get a dose of drug chat with other Fools on the Pharmaceuticals discussion board.
Alyce Lomax welcomes your feedback at firstname.lastname@example.org.
More from The Motley Fool
Roku Could Compete With Netflix Long Term
Management thinks that many media companies will partner with the Roku Channel.
Fitbit's 6 Biggest Blunders
Why is the world’s top wearables maker trading 70% below its IPO price?
The Taxation of Social Security Benefits Has Created Quite the Dilemma
This archaic tax has the potential to both help and hurt the Social Security program.